Skip to main content

UNIVEST FINANCIAL Corp

For the period ended Jun 30, 2026. Filed Jul 28, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 28, 2026

UVSP$40.83-0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows for the

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended June 30,
(Dollars in thousands)20262025
Cash flows from operating activities:
Net income$50,045$42,373
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for credit losses3,9758,005
Depreciation of premises and equipment2,8252,731
Net amortization of investment securities premiums and discounts418480
Amortization, fair market value adjustments and capitalization of servicing rights(707)81
Net gain on investment securities transactions(11)—
Net gain on mortgage banking activities(2,137)(1,628)
Net loss (gain) on sales and write-downs of other real estate owned5,249(4)
Bank owned life insurance income(3,030)(2,971)
Stock-based compensation2,5852,252
Intangible expenses185261
Other adjustments to reconcile net income to cash used in operating activities(1,769)(1,563)
Originations of loans held for sale(110,793)(95,067)
Proceeds from the sale of loans held for sale114,59695,735
Contributions to pension and other postretirement benefit plans(136)(125)
Increase in accrued interest receivable and other assets(9,585)(3,526)
Decrease in accrued interest payable and other liabilities(5,611)(8,176)
Net cash provided by operating activities46,09938,858
Cash flows from investing activities:
Proceeds from sale of premises and equipment9305
Purchases of premises and equipment(1,644)(3,293)
Proceeds from maturities, calls and principal repayments of securities held-to-maturity6,6646,727
Proceeds from maturities, calls and principal repayments of securities available-for-sale34,09224,025
Purchases of investment securities held-to-maturity—(1,236)
Purchases of investment securities available-for-sale(44,078)(22,380)
Proceeds from sales of equity securities5,7312,955
Purchases of money market mutual funds(6,422)(2,250)
Net decrease in other investments5,0102,498
Proceeds from sale of loans originally held-for-investment16,739—
Net (increase) decrease in loans and leases(146,001)14,283
Proceeds from sales of foreclosed / repossessed assets73239
Purchases of bank owned life insurance(1,646)—
Proceeds from bank owned life insurance2,5472,236
Net cash used in investing activities(128,926)24,109
Cash flows from financing activities:
Net decrease in deposits(154,305)(176,602)
Net decrease in short-term borrowings(5,585)(4,910)
Proceeds from issuance of long-term debt25,00050,000
Repayment of long-term debt(100,000)(75,000)
Repayment of subordinated debt(55)—
Payment of contingent consideration on acquisitions—(635)
Payment for shares withheld to cover taxes on vesting of restricted stock units(1,875)(1,582)
Purchases of treasury stock(28,531)(11,440)
Stock issued under dividend reinvestment and employee stock purchase plans1,1701,149
Proceeds from exercise of stock options1,541323
Cash dividends paid(12,920)(12,749)
Net cash used in financing activities(275,560)(231,446)
Net decrease in cash and cash equivalents(358,387)(168,479)
Cash and cash equivalents at beginning of year553,712328,844
Cash and cash equivalents at end of period$195,325$160,365
Six Months Ended June 30,
(Dollars in thousands)20262025
Supplemental disclosures of cash flow information:
Cash paid for interest$86,801$98,926
Non cash transactions:
Transfer of loans to other real estate owned$—$2,526
Transfer of leases to repossessed assets8817
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.